Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11
- Viral Infection
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28235
INOpulse is based on the Companyâ€™s proprietary pulsatile nitric oxide delivery device. The Company is currently developing two product candidates under its INOpulse program one for the treatment of pulmonary arterial hypertension, or PAH, for which the Company intends to commence Phase 3 clinical trials in the second half of 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH COPD, which is in Phase 2 development.
The INOpulse device is designed to be portable for use by ambulatory patients on a daily basis inside or outside their homes. The device is programmed to automatically adjust based on a patientâ€™s breathing pattern to deliver a constant and appropriate dose of the inhaled nitric oxide over time, independent of the patientâ€™s activity level, thus ensuring more consistent dosing in the alveoli of the lungs. In addition, we have developed a proprietary triple-lumen nasal cannula which enables more accurate delivery of the dose to the patient. The INOpulse device is also compatible with many long-term oxygen therapy systems that operate via a nasal cannula.
IPSCIO Record ID: 49323
IPSCIO Record ID: 263060
INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide.
IPSCIO Record ID: 376522
Nontuberculous mycobacteria, also known as environmental mycobacteria, atypical mycobacteria and mycobacteria other than tuberculosis, are mycobacteria which do not cause tuberculosis or leprosy. NTM do cause pulmonary diseases that resemble tuberculosis. Nontuberculous mycobacterial (NTM) lung disease is a serious infection caused by bacteria that are common in the environment and can cause lung damage.
IPSCIO Record ID: 27221
IPSCIO Record ID: 256986
GeNOvent is a cylinder free, phasic flow nitric oxide delivery system and has been designated as a medical device by the US Food and Drug Administration (FDA). The device can generate NO on demand for delivery to the lungs at concentrations ranging from 1 part per million (ppm) to 80 ppm. A disposable smart filter is used to remove nitrogen dioxide (NO2), a toxic gas. The elimination of the need for large, high-pressure cylinders for NO is a significant advantage in the hospital setting by greatly reducing inventory and storage requirements, and improving overall safety with the elimination of NO2 purging steps, among other benefits.
The Licensor is a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension.
Nitric oxide (NO) is a crucially important molecule proven to play a critical role in a broad array of biological functions. Inhaled nitric oxide is currently approved for treating term and near-term neonates with Persistent Pulmonary Hypertension of the Newborn (PPHN) in the United States of America and most major markets. In Europe, Japan and Australia, inhaled NO is approved to treat PPHN as well as pulmonary hypertension during the peri-operative cardiac surgery period in neonates, children, and adults. In the airways, NO is believed to play a key role in the innate immune system at concentrations of approximately 200 ppm. In vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, both gram-positive and gram-negative, but also against other diverse organisms including mycobacteria, fungi, yeast and parasites, and has the potential to eliminate their multi-drug resistant strains.
Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening condition secondary to failure of normal circulatory transition at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1000 live births (0.4â€“6.8/1000 live births) with mortality rate ranging between 4â€“33%. This syndrome complicates the course of about 10% of infants with respiratory failure and remains a source of considerable morbidity and mortality. NO gas is a pulmonary vasodilator and is approved in dozens of countries to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilator support and other appropriate agents.
IPSCIO Record ID: 857
The Channel Agreement grants the Licensee a worldwide License to use specified patents and other intellectual property of the Licensor in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products involving the production of PGIS (prostacylin synthase) through the use of an in vivo conditionally regulated embedded controllable bioreactor for the treatment of Pulmonary arterial hypertension (PAH) in humans.
Licensee may not subLicense the rights described without Licensor's written consent.
The synthetic biologic product candidate is intended to treat PAH, a serious life-threatening lung disease. This product is designed to deliver DNA that encodes a therapeutic protein called prostacyclin synthase (PGIS) locally to the pulmonary arteries of PAH patients via a single procedure, and, via an oral daily pill, control the long-term local expression of such therapeutic protein.
Pulmonary arterial hypertension (PAH) is high blood pressure in the arteries of your lungs. Itâ€™s a serious condition that can make it difficult for blood to flow through your lungs. This can force your heart to work harder than normal.
The Licensee intends to use the Licensor's technology directed towards the production of PGIS, through the use of in vivo conditionally regulated embedded controllable bioreactors for the treatment of PAH.
IPSCIO Record ID: 353499
Licensee current areas of focus with LungFitÂ® are persistent pulmonary hypertension of the newborn (â€œPPHNâ€), acute viral pneumonia (â€œAVPâ€) including COVID-19, bronchiolitis (â€œBROâ€) and nontuberculous mycobacteria (â€œNTMâ€) lung infection.
IPSCIO Record ID: 213206
COPD is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow.
IPSCIO Record ID: 268269
IPSCIO Record ID: 388300
This license is for the delivery of non-invasive ventilatory support relating to the Oxygen Assist Module focused on at home patient monitoring.